Filing Flows › Humacyte (HUMA) › Q1 2025
Humacyte (HUMA) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 13, 2025
Humacyte (HUMA) reported revenue of $517K for the first quarter 2025 (Q1 2025).
Humacyte, Q1 2025: revenue $517K, net earnings $39.1M, operating cash flow −$28.6M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $517K | — | — |
| Operating profit | −$23.2M | — | — |
| Net earnings | $39.1M | — | — |
| Operating cash flow | −$28.6M | — | — |
What changed
Revenue was $517K in Q1 2025.
Operating costs exceeded revenue by $23.2M, an operating margin of -4484.3%. Net earnings were $39.1M. The effective tax rate was 0.0%. Non-operating items added $62.3M, 159% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$28.6M. Non-cash charges added back $1.3M of depreciation and $2.5M of share-based compensation. Working capital and other items used $71.5M. Capital expenditures of $228K exceeded it, leaving free cash flow of −$28.8M.
Questions
What was Humacyte's revenue in the first quarter 2025?
Humacyte (HUMA) reported revenue of $517K for the first quarter 2025 (Q1 2025).
Source: Humacyte 10-Q on SEC EDGAR.